BUZZ-Mallinckrodt bucks trend as Morgan Stanley upgrades to "overweight"
** Mallinckrodt one of just a few stocks higher in the S&P Healthcare index after Morgan Stanley upgrades drugmaker's stock to "overweight"
** Broker says its greater confidence in co's business, based on key franchise Acthar, outweighs drug pricing concerns and controversy surrounding use of specialty pharmacies
** "We believe Acthar can defy the skeptics and continue to grow, helping drive solid total company growth," analysts write in note
** Cite stock's significant underperformance YTD, say valuation remains cheap and believe multiple expansion would occur as co meets or beats in 2016
** Raise PT to $88 (from $74), implying 20 pct upside to stock's current levels
** Mallinckrodt's woes, along with Valeant's, exacerbated by Democratic presidential candidate Hillary Clinton's criticism in late September of "price gouging" in the industry
** MNK has bounced 40 pct off a near 2-year low despite early Nov tweet from short seller Citron Research saying that the drugmaker was "a far worse offender of the reimbursement system"
** Company reported stronger-than-expected earnings on Nov 23
** Shares last up about 1 pct to $73.04 and off about a quarter this year (Reuters Messaging: firstname.lastname@example.org)
© Thomson Reuters 2017 All rights reserved.